{"name":"Progenics Pharmaceuticals, Inc.","slug":"progenics-pharmaceuticals-inc","ticker":"","exchange":"","domain":"progenics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":11698000,"revenueGrowth":333.7,"grossMargin":0,"rdSpend":49223000,"netIncome":-68552000,"cash":42049000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"18F-DCFPyL","genericName":"18F-DCFPyL","slug":"18f-dcfpyl","indication":"Other","status":"marketed"},{"name":"I-131-1095","genericName":"I-131-1095","slug":"i-131-1095","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"18F-DCFPyL","genericName":"18F-DCFPyL","slug":"18f-dcfpyl","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"I-131-1095","genericName":"I-131-1095","slug":"i-131-1095","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQYWpHUzRZekZkM3RnaTRRV1ZyRGd5SG15YkVtSlplajZRQ1FLaUhNQXIxTEtqS2Q5YUFPQTdCUTV2ZlQwQzVSVzNvNE1HaWRNSy1TSEl0WkNWRUlXRFUyY1B4Mjg3Y3UzczdDOUhMeEtvSTAxNDRWc1F6UTZESHdrWDg2TlBUZ1BuWEpfM3Q3QjlKY19TdUhMY2dlWTdiU3hxT3FxUQ?oc=5","date":"2026-03-16","type":"pipeline","source":"Fortune Business Insights","summary":"Neuroendocrine Tumors Treatment Market Size, Forecast, 2034 - Fortune Business Insights","headline":"Neuroendocrine Tumors Treatment Market Size, Forecast, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPN0dzMUxzYXZ4ZWhOTTJoYkdRS0xaU0hKVldQYkdWaktBcERwaTk4RDEycEZCOHZ3T1VIXzg4MzgxZ3VLUG1jdE1Hc1g1S0s5UEJ5OTBfWmJWRE5MOU1oR0RnYW91cWRCb0ZDaTgtX1RUSllnUThDUlFyUklFTlpncA?oc=5","date":"2025-12-09","type":"pipeline","source":"MarketsandMarkets","summary":"Radioligand Therapy (RLT) Market worth $10.91 billion by 2035 - MarketsandMarkets","headline":"Radioligand Therapy (RLT) Market worth $10.91 billion by 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPN0hNQkNaSE5SbGtYTDRNbmY4OWV3ODJlb1ZFZW1jWW5zSklGWEtDOS1mYUJFUHdWMGxyLTN2ZDR4aFB2c0tLNnFRQ2lZTGJ6aGViRWRWT0lPRVctLVBGYzEzdFU5RTFsLWtoUW1CU2ZqUkMzQnFNVTk3bmxZZWhCQnhaMW1wdkhrSENYWC1VaUQ2a1V1NW1CYWJMbmhpUU1TenY3NjVRWW5JZUF3d25WaDZKZmhQMVN2UjF6RTluaUY4dVJGelo3N2huRlJ2b1BKRHpIVXltc3dLODNPNkt0bGN3RGg4WGdtTjU4QUdDNm9rTGhtVVd3SjB1QzdPemNKbXMzV3pSN19handVUjgzN0laVVpQNFF2N2p4dWtvcE8zd01hZmJzekZvMDA4YkVjNFlB?oc=5","date":"2024-07-09","type":"pipeline","source":"PR Newswire","summary":"Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca - PR Newswire","headline":"Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxOelNiRC1ReXFNc3dac3BtSG5QVXNRNnZESF81WWxjOGcwa1dDTE0yZlV5N3R5dS1ZS2FlQlJ6LWY2LU1kUmFmMVYzckx4VlZHT05Pa25UcEI5NWNsbkdMTExJbndzd0gxVlhsZTMyb1kxSHo1bFQwUEtrcWZDV1JSa0p2ZE9vcEU3c3h1dGVVdkwyTVBjWDZnXzFxbXI4a2lwVzJWVGRsZmpGWnIxcTlYMUctS05TbmE2Sm5LWXowaXVkVTBVbjRzdEF4WXdxUEdid2lKSWhPeFhyRXAxNkRURmQtVnBfbzE1M1ROWHBxTUtXZnB0bXV5bkd6YTd6SVNzVXBab1Y0dm5OYnJWUENEcXJSZGc3bHhXbHloaUtvSGl5UENyczJmdzRaNzllMHc?oc=5","date":"2024-03-12","type":"pipeline","source":"UroToday","summary":"Novel Hormone Therapy and Coordination of Care in High-Risk Biochemically Recurrent Prostate Cancer - Beyond the Abstract - UroToday","headline":"Novel Hormone Therapy and Coordination of Care in High-Risk Biochemically Recurrent Prostate Cancer - Beyond the Abstrac","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE9tZk5UZDFpSDRyS0pianJmMTlnNzhoaXYwZ1l6VDB6WlM2SUZxUXZxbWV2OWhRSmd1SDYwd0FVR3ZhRE9rVFY2Mml1WGVpcUJYS1dfUkRfWQ?oc=5","date":"2022-02-01","type":"pipeline","source":"Journal of Nuclear Medicine","summary":"Managing a High-Specific-Activity Iobenguane Therapy Clinic: From Operations to Reimbursement - Journal of Nuclear Medicine","headline":"Managing a High-Specific-Activity Iobenguane Therapy Clinic: From Operations to Reimbursement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxObHBOUGtwcVc1eDExVmNLaGZKM3lPWnN3cXlVNkc4MG54d2M2QW5TSjlNTmtibmZIUmpKZ1pQR21jZkVSNzFOUnM1Qjc5SmRyV1hfZkhRVXpaV0xXQ1JhVmFEU0pZVVRXMG1qWGFaZ2NHckVvNk93WVBkR2w2enJ1LUt2U1g4WU1zQ1ZXNDQ0d0k5Rk85Tm9zSjlQMUhIekRrdFF6ZUVUQWJuVGU0OS16WDdsRkNZcWl0dUVVbllWRm5xcjBO?oc=5","date":"2019-10-10","type":"deal","source":"Fierce Pharma","summary":"Progenics inked a merger to avoid negotiating a proxy war. One activist still wants to fight - Fierce Pharma","headline":"Progenics inked a merger to avoid negotiating a proxy war. One activist still wants to fight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOcFpvYV9FZTFoNGVXVWZiVWpEU2dSeFR1ZV9TaFVqNGx6aEFURVNsV1Q3cENSMWcxcW41R2R2cER6Y0ZyWEdfWExpeHphMFdlaTQxZDFxbUpkT1hXRjI2d3RVNUM1VWFDX2V3ckZ0dVZrZE9lYnBZZUpUMUxvcGw1WUhHN1BqcHR6R2EtcnVuSXJuZzZSOC1fWnNMN2dfbC1oR2FmVDZ6anBubENWSW45VE96cjJUNmV1ZWVzbFZiSFBiYUJRM28xN013ZWh6TG00aHhMME5yTGV6djllMEVvSzM2V1RoUE4xZUxRV1JQMFlrU25IOFowa0lvZkxXWGpOOVluZWJIYkY2bUFiakpWb056dXJ1aTZOX2w5Q0d1MFI3czg?oc=5","date":"2019-07-25","type":"deal","source":"GlobeNewswire","summary":"Progenics Pharmaceuticals Announces Collaboration with - GlobeNewswire","headline":"Progenics Pharmaceuticals Announces Collaboration with","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNaWRGWFBSMElPdG4waFB4WXRMdUZyNnJRcVcyZHhKUHRPckpISnhaUENVMU9fZlRqSWFWYWxLQjUtV2hIaEhtMmpDbVFIcjZORWZkQ1A2UTdaSWZ5bWIxLUt4SkIzWHpPZi15d0h4TkZDdmNjYXkyWG9FWnlUQ2J6RTgzc3I5TEtQeHBDakZMd3Y?oc=5","date":"2018-12-13","type":"pipeline","source":"Urology Times","summary":"New Products: Cuff stops urinary leakages in PCa patients - Urology Times","headline":"New Products: Cuff stops urinary leakages in PCa patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPd05xZnRpb2UwOHFNM0JsaC1qWFcwVlFQTzJlNXFtWGtDRm9aZHRMbnRoNWlRc3B1NkpoUGdGdm8zc3dPV3J5Yl9FTmFsN0dQd0ctLVViSEJfWWpYbnJCZ2h1RXNtMDF1ekVEcWZvemdOb0J5WmVTUlR4aEpqb1VIOGhUS0I3YTBGREttYQ?oc=5","date":"2018-07-26","type":"pipeline","source":"The Motley Fool","summary":"3 Stocks That Could Double Your Money - The Motley Fool","headline":"3 Stocks That Could Double Your Money","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPTDlxelBFVHk5UU9ENkEtSm1maEhFeVh6UnJBbW41eG9faWpBdWtkR2czR1E4dHAyVVRzcnJSWVpYR0IxdF84Z1MxQkxCZjNwZmhIQUNnUFU0bkx6a0F3S0JJdnFjZk5ZUTFBU1hZaW53bVZwUTIzQmpUY0hrUElqTjRfeUV0QWZsSlU0YmRpdUxMdHViZFNTTzFKd2N1MW00NFV3Njc5UjZNb2JFVzQ5TA?oc=5","date":"2018-02-20","type":"pipeline","source":"Investing News Network","summary":"5 Pharmaceutical NASDAQ Micro-Cap Stocks - Investing News Network","headline":"5 Pharmaceutical NASDAQ Micro-Cap Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPM184Y1dQMkN4RkhNQzZNN3ZUWmE5TWYzWXNWRVQtdEEzNWNFbjVpUDlyMnRFak5QMDRENXhfeWE4a29yWWtlZGQ3NVhlNTRROVVsc2ZEcU9aNmhtMlQ0bVRqbUgtWlE3WGRDdm1ZV29kcS1qaVpEVk1BYjVOV283WHhvNkJIc0V3ZlAwVWQ5eHhUaTJ5a213aUlGbGRXeFFWVmc0SEpNNkViZzYxT2FQWm1LSFJWRTJoNlJZSklPR2NneVlmWmphNGFR?oc=5","date":"2013-08-05","type":"trial","source":"Applied Clinical Trials","summary":"Contract Development and Manufacturing Costs During Clinical Development of a New Drug - Applied Clinical Trials","headline":"Contract Development and Manufacturing Costs During Clinical Development of a New Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5NMjJzM19fbzY0TmdRRW83YVd4REgyaHZGQTlJQlRBWnpoOXlNdW13ZGxmTXhvOXFXdWtsaVBWUzRLa25meTEtQ1VXTmpYX3NJMTJ0QU40YXR2cm5vSXpIV2ZGNFR3UHRR0gFwQVVfeXFMUElBQVViSkZNc3BoWVNUWVFsckRZaFFBd3ZjVUNQUGVDeThpRDVQLWVuUFluSmtPVFBTUEJ6OWxPRkJha19QbjJYYklnRV80MVpxZWR2MnIzZEllUEI5endWQkwwWHlfWGxvRi14UUpvUQ?oc=5","date":"2011-01-25","type":"pipeline","source":"westchestermagazine.com","summary":"Biochester - westchestermagazine.com","headline":"Biochester","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":11698000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":11698000,"period":"2017-12-31"},{"value":2697000,"period":"2017-09-30"},{"value":2765000,"period":"2017-06-30"},{"value":2347000,"period":"2017-03-31"},{"value":69429000,"period":"2016-12-31"},{"value":53850000,"period":"2016-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":49223000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-68552000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":42049000,"cashHistory":[],"totalAssets":119470000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}